791 related articles for article (PubMed ID: 18998069)
41. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
[TBL] [Abstract][Full Text] [Related]
42. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in
Wang R; Sheps JA; Liu L; Han J; Chen PSK; Lamontagne J; Wilson PD; Welch I; Borchers CH; Ling V
J Lipid Res; 2019 Jan; 60(1):85-97. PubMed ID: 30416103
[TBL] [Abstract][Full Text] [Related]
43. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
44. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
45. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
46. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.
Jacquemin E
Semin Liver Dis; 2001 Nov; 21(4):551-62. PubMed ID: 11745043
[TBL] [Abstract][Full Text] [Related]
47. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Steinacher D; Claudel T; Trauner M
Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
[TBL] [Abstract][Full Text] [Related]
50. Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition.
Beaudoin JJ; Yang K; Adiwidjaja J; Taneja G; Watkins PB; Siler SQ; Howell BA; Woodhead JL
Front Pharmacol; 2022; 13():1085621. PubMed ID: 36733378
[TBL] [Abstract][Full Text] [Related]
51. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.
Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP
Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499
[TBL] [Abstract][Full Text] [Related]
52. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
53. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
54. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
Hofmann AF; Zakko SF; Lira M; Clerici C; Hagey LR; Lambert KK; Steinbach JH; Schteingart CD; Olinga P; Groothuis GM
Hepatology; 2005 Dec; 42(6):1391-8. PubMed ID: 16317695
[TBL] [Abstract][Full Text] [Related]
55. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
56. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma.
de Vries E; Mazzetti M; Takkenberg B; Mostafavi N; Bikker H; Marzioni M; de Veer R; van der Meer A; Doukas M; Verheij J; Beuers U
Liver Int; 2020 Dec; 40(12):3042-3050. PubMed ID: 32893960
[TBL] [Abstract][Full Text] [Related]
57. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
[TBL] [Abstract][Full Text] [Related]
58. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
[TBL] [Abstract][Full Text] [Related]
59. Targeting bile salt homeostasis in biliary diseases.
Trampert DC; Kunst RF; van de Graaf SFJ
Curr Opin Gastroenterol; 2024 Mar; 40(2):62-69. PubMed ID: 38230695
[TBL] [Abstract][Full Text] [Related]
60. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
